Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.
about
Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex VivoDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryCorrelation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 studyA MIV-150/zinc acetate gel inhibits SHIV-RT infection in macaque vaginal explantsModels for predicting effective HIV chemoprevention in womenA Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model.RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarateDistinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue.Comparison of Follicular and Luteal Phase Mucosal Markers of HIV Susceptibility in Healthy WomenPharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial.HIV-1 infection of female genital tract tissue for use in prevention studiesIn Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical MucosaPharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection.Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.Analytical Advances in the Ex Vivo Challenge Efficacy Assay.MZC Gel Inhibits SHIV-RT and HSV-2 in Macaque Vaginal Mucosa and SHIV-RT in Rectal Mucosa.Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women.Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors In Vitro and Ex Vivo.Prevalence and correlates of willingness to participate in a rectal microbicide trial among men who have sex with men in Bangkok.Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivoPhase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc
P2860
Q26777022-7663985A-7597-4D2D-98FE-7334F72FD9F7Q27334384-3B362B4D-6639-43B5-9AA9-B4F1DBD4D57FQ28081272-77BB6DB9-8E58-4E2B-A76E-C4262991204DQ28544439-D70E256F-CE8C-4B24-BC54-8CD0FB6624B1Q34258224-53E778E6-5812-424C-A093-85D796D06B11Q35102285-16E01FC5-C30F-489A-BB6E-EBA0AC89EF30Q35571216-8D16BA6B-014D-4D45-A3FD-054C209D6EB8Q35746218-FEA7996F-E1AE-42C7-BD5C-F15631760A08Q36359092-408B736E-D05A-4827-950D-18D24FC0A64AQ36888077-B6874AD7-0A84-49BF-A538-B4FEAE76FC1DQ36966645-C61DDB2E-C5C1-4F36-AC4D-29265D110331Q37116845-9E123153-1E8C-4A64-9E18-E2A5DECBAFDDQ37141860-73658E3B-ACE0-4BFD-B45F-8E7A6B58BB41Q37203838-3DBAA96F-4B65-4F96-A5F6-24AE44A3C8B5Q37258271-6E371620-556A-40AD-B0CA-49E8EB250A44Q37713059-16B07243-82C6-4631-9156-A282EF2CA1DFQ37716218-EE6B0BB5-9971-4A87-913D-B5F01E74DC79Q39189916-2D6876E2-5876-4639-9A08-6FA14A56EF41Q39463175-8C3F037C-BF3D-4C0E-AECE-E9BBB3094D9DQ40248406-F30645F3-866C-4E2E-BA89-01CA61871A16Q40334457-881CE17C-0897-4A09-BFB9-596A74D0D177Q46902763-84CC83B7-906E-4271-AA69-A648083FF94AQ58700581-023649E0-C810-47FE-9F02-47C691E1ABDBQ58723423-C8C8386A-35CF-4DD1-92B6-EC0B0AD8D314
P2860
Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Dose-response relationship bet ...... he RMP-01 rectal safety study.
@ast
Dose-response relationship bet ...... he RMP-01 rectal safety study.
@en
type
label
Dose-response relationship bet ...... he RMP-01 rectal safety study.
@ast
Dose-response relationship bet ...... he RMP-01 rectal safety study.
@en
prefLabel
Dose-response relationship bet ...... he RMP-01 rectal safety study.
@ast
Dose-response relationship bet ...... he RMP-01 rectal safety study.
@en
P2093
P2860
P356
P1476
Dose-response relationship bet ...... he RMP-01 rectal safety study.
@en
P2093
Christine Mauck
Ian McGowan
Nicola Richardson-Harman
Peter Anton
P2860
P304
P356
10.1089/AID.2012.0073
P577
2012-09-20T00:00:00Z